Amir Genosar — President and CEO

Amir is an accomplished serial entrepreneur and inventor in the drug delivery device space. To date, Amir has formed a number of medical startup companies and served in a variety of roles for these companies including CEO, CTO, and serving on the board of directors. In 2006, Amir co-founded SteadyMed (acquired by United Therapeutics for $216 million in 2018), and was an inventor of its drug-device combination product patch pump. Along his professional career Amir helped several leading healthcare companies innovate and address unmet needs in the drug delivery device space including, Johnson & Johnson, Novartis, Phillips, and Medtronic. He is an inventor of the MAP Pharmaceutical combination product inhaler technology (acquired by Allergan for $958 million in 2013). Prior to his innovation and entrepreneurship career Amir held manufacturing positions for drug delivery devices. 

Amir is passionate about building a holistic approach to care for the communities that Aktivax’s products serve. In his view, the foundation to the success of this approach is a company culture that emphasis care and passion to the Aktivax team, and appreciation to the opportunity to engage with each individual’s talents, gifts, and personal journey.

Amir is a father to four strong young women with whom he loves exploring the outdoors including hiking, backpacking, camping, skiing, surfing, long road trips, and other world class adventures.


Greg Langley — VP of Product Development

Greg is an experienced entrepreneur, business executive and product development leader with over 30 years’ experience. Greg led Syncroness (a leading product development firm in the Medical Device and Aerospace market) to being on the INC 5000 list over 7 consecutive years. Greg has expertise in leading teams in process development and methodologies needed to commercialize novel medical products, such as Design Controls (CFR 820), Manufacturing (ISO 9001), and Quality/Regulatory (ISO 13485) systems, as well as customized manufacturing processes and equipment needed for high quality medical manufacturing. Greg drives product success using market-based development, i.e., developing products based on a clear understanding of market and customer needs. 


Joe Schroeter — VP of Corporate Development

Joe has more than 20 years’ experience growing tech companies in a variety of C-suite roles. He has helped companies scale in grow healthy businesses and organizations in tech and healthcare. Joe led CQG to create a profitable strategy and develop a suite of SaaS products to give traders an edge. CQG built a platform where more than 18,000 traders, banks, commercial users, trading firms and other software vendors could access our software, data and trading APIs, and analytics as they needed. He has a passion for creating cultures that are capable to deliver on any challenge. 


Dr. Arik Eisenkraft — Medical Director

Dr. Eisenkraft holds an MD degree from the Sackler Faculty of Medicine, Tel-Aviv University, Israel; a residency in Pediatrics from the Sheba Medical Center, Tel-Hashomer, Israel; and a MHA degree from the Ben-Gurion University of the Negev, Israel. During 2000-2008 he served in the CBRN Medicine Branch of the IDF, and from 2008-2016 he served as the Head of the Medicine Branch at the CBRN Protection Division of the Israeli Ministry of Defense. As such, he was leading national research and development efforts as well as procurement of medical countermeasures (MCMs) against all CBRN threats; working closely together with national and foreign governmental departments and agencies, the IDF, the Home-Front Command and the Israeli Ministry of Health. His efforts focused on the seeding of new research programs, aimed to develop new MCMs, as well as re-purposing and broadening the clinical indications of currently available compounds, and testing cutting-edge technologies for drug delivery methods. From June 2013 until November 2014 he was the Acting Director of the CBRN Protection Division of the IMOD. He is currently serving as a member in several Israeli national committees in the IDF Medical Corps, and the Israeli Ministry of Health, in the field of CBRN Medicine. In 2013, Dr. Eisenkraft has led the efforts to establish the Institute for Research in Military Medicine (IRMM), and from 2013-2016 he served as the Military Deputy of the Institute. Since 2013, he is an assistant professor at the IRMM, actively involved in research projects, all in the field of Military Medicine. Dr. Eisenkraft has published more than 80 publications, including manuscripts in peer-reviewed journals and chapters in professional textbooks on CBRN Medicine Defense, and his work was presented in numerous international conferences worldwide.

On August 2016, Dr. Eisenkraft has retired from active duty, as a Lieutenant Colonel, in the IDF Medical Corps after 20 years of service, and continues his research and teaching activities, all in the field of Military Medicine, in the Institute for Research in Military Medicine of The Hebrew University, Faculty of Medicine.


David Banks — VP of Manufacturing Operations

David is an experienced Manufacturing Operations Executive. With more than 25 years of Manufacturing and Supply Chain experience in the pharmaceutical industry, he held positions of increasing responsibility at a number of companies including GSK (as SmithKline Beecham), Roche (as Syntex), Johnson & Johnson (as Alza), and Gilead (CV Therapeutics). Product development including engineering, technology transfer, validation, as well as commercial product production management, planning, materials and distribution management, and executive management are areas of expertise. He directly managed and oversaw the supply chains necessary for sourcing raw materials and drug substance, as well as the manufacturing processes required for commercial production. Additionally, David is experienced as working both as a CMO supplying most of the major pharmaceutical companies and directly managing his own production and distribution chains. His contributions to ten pharmaceutical product launches, demonstrate his ability to handle complex operations in compressed timeframes.